VANCOUVER, BRITISH COLUMBIA--(Marketwire - September 24, 2008) - Chemokine Therapeutics Corp. (the “Company”) (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced the launch of a multi-stage strategic financial initiative. The initiative is designed to (1) address current working capital needs, (2) raise required funds for the launch of the CTCE-9908 Phase II liver cancer trial and (3) materially enhance shareholder value.
